Eastman Kodak Co. will receive a $765 million government loan to help expedite the domestic production of generic drugs to treat a variety of medical conditions and loosen the country's reliance on foreign sources, officials said Tuesday. Specifically, the Rochester-based company will make the ingredients so often produced overseas so the country can produce its own medications.
The move is expected to create at least 350 new jobs, launching a new business unit for the Rochester-based company that — when at peak production in four to five years — could produce 25% of the active ingredients for "non-biologic, non-antibacterial, generic pharmaceuticals."
...Continenza told The Journal that the loan has terms similar to a commercial loan and must be repaid over 25 years. Kodak will produce “starter materials” and “active pharmaceutical ingredients” used to produce generic medicines, he said. “We have a long, long history in chemical and advanced materials — well over 100 years,” Continenza said. He added that Kodak’s existing infrastructure allows the company “to get up and running quickly.”
...The operation will build on Kodak's existing Specialty Chemicals Group, a segment that is dispersed across a three-building complex at Eastman Business Park, with multiple cells or bays that operate as its own chemical factory so that multiple processes can be run concurrently. That operation already is working with various markets, including pharmaceuticals. In company brochures, Kodak touts the 88 reactors, more than 25 centrifuges, filter and membrane presses.I think this is a pretty logical move on the part of the Trump Administration, i.e. they clearly want to reshore the pharmaceutical supply chain, and Kodak is (I strongly suspect) the largest group of not-currently-spoken-for large scale reactors in the country. They're making noises about making APIs there, and I'm pretty skeptical of that, but the better part of a billion dollars will get you at least partway there. This bears watching.